209 related articles for article (PubMed ID: 26391436)
1. Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome.
Malli T; Buxhofer-Ausch V; Rammer M; Erdel M; Kranewitter W; Rumpold H; Marschon R; Deutschbauer S; Simonitsch-Klupp I; Valent P; Muellner-Ammer K; Sebesta C; Birkner T; Webersinke G
Genes Chromosomes Cancer; 2016 Jan; 55(1):60-8. PubMed ID: 26391436
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome.
Li F; Zhai YP; Tang YM; Wang LP; Wan PJ
Genes Chromosomes Cancer; 2012 Sep; 51(9):890-7. PubMed ID: 22619110
[TBL] [Abstract][Full Text] [Related]
3. Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion.
Qiu XH; Li F; Cao HQ; Shao JJ; Mei JG; Li HQ; Zhai YP
Mol Med Rep; 2017 Mar; 15(3):1024-1030. PubMed ID: 28138694
[TBL] [Abstract][Full Text] [Related]
4. Molecular identification of a TPR-FGFR1 fusion transcript in an adult with myeloproliferative neoplasm, T-lymphoblastic lymphoma, and a t(1;8)(q25;p11.2).
Kim SY; Kim JE; Park S; Kim HK
Cancer Genet; 2014 Jun; 207(6):258-62. PubMed ID: 25037443
[TBL] [Abstract][Full Text] [Related]
5. Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib.
Landberg N; Dreimane A; Rissler M; Billström R; Ågerstam H
Eur J Haematol; 2017 Nov; 99(5):442-448. PubMed ID: 28881484
[TBL] [Abstract][Full Text] [Related]
6. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.
Chase A; Grand FH; Cross NC
Blood; 2007 Nov; 110(10):3729-34. PubMed ID: 17698633
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.
Chase A; Bryant C; Score J; Cross NC
Haematologica; 2013 Jan; 98(1):103-6. PubMed ID: 22875613
[TBL] [Abstract][Full Text] [Related]
8. The 8p11 myeloproliferative syndrome owing to rare FGFR1OP2-FGFR1 fusion.
Onozawa M; Ohmura K; Ibata M; Iwasaki J; Okada K; Kasahara I; Yamaguchi K; Kubota K; Fujisawa S; Shigematsu A; Endo T; Kondo T; Hashino S; Tanaka J; Matsuno Y; Asaka M; Imamura M
Eur J Haematol; 2011 Apr; 86(4):347-9. PubMed ID: 21198859
[No Abstract] [Full Text] [Related]
9. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.
Fioretos T; Panagopoulos I; Lassen C; Swedin A; Billström R; Isaksson M; Strömbeck B; Olofsson T; Mitelman F; Johansson B
Genes Chromosomes Cancer; 2001 Dec; 32(4):302-10. PubMed ID: 11746971
[TBL] [Abstract][Full Text] [Related]
10. Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1.
Yamamoto S; Otsu M; Matsuzaka E; Konishi C; Takagi H; Hanada S; Mochizuki S; Nakauchi H; Imai K; Tsuji K; Ebihara Y
PLoS One; 2015; 10(3):e0120841. PubMed ID: 25803811
[TBL] [Abstract][Full Text] [Related]
11. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.
Guasch G; Ollendorff V; Borg JP; Birnbaum D; Pébusque MJ
Mol Cell Biol; 2001 Dec; 21(23):8129-42. PubMed ID: 11689702
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome.
Grand EK; Grand FH; Chase AJ; Ross FM; Corcoran MM; Oscier DG; Cross NC
Genes Chromosomes Cancer; 2004 May; 40(1):78-83. PubMed ID: 15034873
[TBL] [Abstract][Full Text] [Related]
13. [8p11 myeloproliferative syndrome with CEP110-FGFR1 fusion in a patient].
Chao H; Chen S; Zhou M; Lu X; Zhang X; Pan J; Wu C; Zhang R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Oct; 32(5):679-82. PubMed ID: 26418991
[TBL] [Abstract][Full Text] [Related]
14. Myeloid/lymphoid neoplasm with CEP110-FGFR1 fusion: An analysis of 16 cases show common features and poor prognosis.
Chen M; Wang K; Cai X; Zhang X; Chao H; Chen S; Shen H; Wang Q; Zhang R
Hematology; 2021 Dec; 26(1):153-159. PubMed ID: 33491601
[No Abstract] [Full Text] [Related]
15. Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice.
Agerstam H; Järås M; Andersson A; Johnels P; Hansen N; Lassen C; Rissler M; Gisselsson D; Olofsson T; Richter J; Fan X; Ehinger M; Fioretos T
Blood; 2010 Sep; 116(12):2103-11. PubMed ID: 20554971
[TBL] [Abstract][Full Text] [Related]
16. [FGFR1 and MOZ, two key genes involved in malignant hemopathies linked to rearrangements within the chromosomal region 8p11-12].
Pébusque MJ; Chaffanet M; Popovici C; Birnbaum D
Bull Cancer; 2000 Dec; 87(12):887-94. PubMed ID: 11174118
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and gene involved of one case of 8p11 myeloproliferative syndrome with ins(13;8)(q12;p11p23)].
Zhou F; Chen S; Chao H; Zhang R; Zhou M; Pan J
Zhonghua Xue Ye Xue Za Zhi; 2015 Apr; 36(4):291-6. PubMed ID: 25916288
[TBL] [Abstract][Full Text] [Related]
18. Molecular monitoring of 8p11 myeloproliferative syndrome in an infant.
Zhang WW; Habeebu S; Sheehan AM; Naeem R; Hernandez VS; Dreyer ZE; López-Terrada D
J Pediatr Hematol Oncol; 2009 Nov; 31(11):879-83. PubMed ID: 19829149
[TBL] [Abstract][Full Text] [Related]
19. [The 8p11 myeloproliferative syndrome: a review of recent literature].
Kirito K
Rinsho Ketsueki; 2019; 60(9):1157-1165. PubMed ID: 31597839
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report.
Wang Y; Wu X; Deng J; Yu H; Xu R; Zhu Z; Tu S; Hu Y
Cancer Biol Ther; 2016 Aug; 17(8):785-9. PubMed ID: 27415155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
